• Skip to main content
  • Skip to primary sidebar
virology blog

virology blog

About viruses and viral disease

ribozyme

Viroids, infectious agents that encode no proteins

14 January 2015 by Vincent Racaniello

potato spindle tuber viroidGenomes of non-defective viruses range in size from 2,400,000 bp of dsDNA (Pandoravirus salinus) to 1,759 bp of ssDNA (porcine circovirus). Are even smaller viral genomes possible? The subviral agents called viroids provide an answer to this question.

Viroids, the smallest known pathogens, are naked, circular, single-stranded RNA molecules that do not encode protein yet replicate autonomously when introduced into host plants. Potato spindle tuber viroid, discovered in 1971, is the prototype; 29 other viroids have since been discovered ranging in length from 120 to 475 nucleotides. Viroids only infect plants; some cause economically important diseases of crop plants, while others appear to be benign. Two examples of economically important viroids are coconut cadang-cadang viroid (which causes a lethal infection of coconut palms) and apple scar skin viroid (which causes an infection that results in visually unappealing apples).

The 30 known viroids have been classified in two families. Members of the Pospiviroidae, named for potato spindle tuber viroid, have a rod-like secondary structure with small single stranded regions, a central conserved region, and replicate in the nucleus (illustrated; click to enlarge; figure credit). The Avsunviroidae, named for avocado sunblotch viroid, have both rod-like and branched regions, but lack a central conserved region and replicate in chloroplasts. In contrast to the Pospiviroidae, the latter RNA molecules are functional ribozymes, and this activity is essential for replication.

There is no evidence that viroids encode proteins or mRNA. Unlike viruses, which are parasites of host translation machinery, viroids are parasites of cellular transcription proteins: they depend on cellular RNA polymerase for replication. Such polymerases normally recognize DNA templates, but can copy viroid RNAs.

In plants infected with members of the Pospiviroidae, viroid RNA is imported into the nucleus, and copied by plant DNA-dependent RNA polymerase II. The viroid is copied by a rolling circle mechanism that produces complementary linear, concatameric, RNAs. These are copied again to produce concatameric, linear molecules, which are cleaved by the host enzyme RNAse III. Their ends are joined by a host enzyme to form circles.

In plants infected with members of the Avsunviroidae, viroid RNA is imported into the chloroplast, and complementary concatameric RNAs are produced by chloroplast DNA-dependent RNA polymerase. Cleavage of these molecules is carried out by a ribozyme, an enzyme encoded in the viroid RNA.

After replication, viroid progeny exit the nucleus or chloroplast and move to adjacent cells through plasmodesmata, and can travel systemically via the phloem to infect other cells. Viroids enter the pollen and ovule, from where they are transmitted to the seed. When the seed germinates, the new plant becomes infected. Viroids can also be transmitted among plants by contaminated farm machinery and insects.

Symptoms of viroid infection in plants include stunting of growth, deformation of leaves and fruit, stem necrosis, and death. Because viroids do not produce mRNAs, it was first proposed that disease must be a consequence of viroid RNA binding to host proteins or nucleic acids.  The discovery of RNA silencing in plants lead to the hypothesis that small interfering RNAs derived from viroid RNAs guide silencing of host genes, leading to induction of disease. In support of this hypothesis, peach latent mosaic viroid small RNAs have been identified that silence chloroplast heat shock protein 90, which correlates with disease symptoms. The different disease patterns caused by viroids in their hosts might all have in common an origin in RNA silencing.

Our current understanding is that the disease-causing viroids were transferred from wild plants used for breeding modern crops. The widespread prevalence of these agents can be traced to the use of genetically identical plants (monoculture), worldwide distribution of breeding lines, and mechanical transmission by contaminated farm machinery. As a consequence, these unusual pathogens now occupy niches around the planet that never before were available to them.

The origin of viroids remains an enigma, but it has been proposed that they are relics from the RNA world, which is thought to have been populated only by non-coding RNA molecules that catalysed their own synthesis. Viroids have properties that make them candidates for survivors of the RNA world: small genome size (to avoid error catastrophe caused by error-prone replication), high G+C content (for greater thermodynamic stability), circular genomes (to avoid the need for mechanisms to prevent loss of information at the ends of linear genomes), no protein content, and the presence of a ribozyme, a fingerprint of the RNA world. Today’s viroids can no longer self-replicate, possibly having lost that function when they became parasites of plants. What began as a search for virus-like agents that cause disease in plants has lead to new insights into the evolution of life.

Filed Under: Basic virology, Information Tagged With: DNA dependent RNA polymerase, noncoding RNA, plant, potato spindle tuber viroid, ribozyme, RNA, siRNA, viral, viroid, virology, virus

TWiV #22: Viral Bioinformatics

1 March 2009 by Vincent Racaniello

twiv-200In episode #22 of This Week in Virology, Vincent and Chris Upton converse about hepatitis B in India, AIDS gene therapy with a ribozyme, antibodies that neutralize many influenza virus strains, killing tumors with vaccinia virus, myxoma virus of rabbits, and the Viral Bioinformatics Resource Center.

Click the arrow above to play, or right-click to download TWiV #22 or subscribe in iTunes or by email.

Filed Under: Events Tagged With: AIDS, HBV, hepatitis, HIV, influenza, myxoma, ribozyme, TWiV, vaccinia

Anti-HIV ribozyme: an alternative to HAART?

24 February 2009 by Vincent Racaniello

hdv_ribozymeThe treatment of AIDS patients with a combination of three or four antiviral drugs is known as HAART, or highly active antiretroviral therapy. Combination therapy has been effective for long-term control of infection, and represents one of the high points in AIDS research. The downside of HAART is that strict adherence to daily therapy must be maintained, and toxicity and viral resistance are continuing problems. Is there an alternative for AIDS patients?

The results of a phase 2 gene therapy trial suggest that gene therapy with an anti-HIV ribozyme could control HIV-1 replication in AIDS patients. A ribozyme is an enzyme made of RNA, not protein. Examples include the group I intron of Tetrahymena thermophila (the first ribozyme discovered), RNAse P of bacteria, group II self-splicing introns, and the hepatitis delta ribozyme. They differ widely in size, sequence, and mechanism of catalysis. They can cleave their own phosphodiester bonds, or those of other RNAs – which is why they are being explored as antiviral and antitumor agents.

The ribozyme used in the phase 2 study, which targets two overlapping open reading frames of HIV-1, was previously shown to inhibit viral replication in cultured cells. The ribozyme was incorporated into a retrovirus vector, which was then used to infect peripheral blood CD34+ stem cells that had been obtained from each patient. The stem cells were placed in culture, infected with the ribozyme-containing retrovirus, and then the cells were injected intravenously back into each patient. A total of 38 patients received cells that had been infected with the ribozyme-containing retrovirus, while 36 patients received cells that had been infected with a control retrovirus. Six months later, HAART therapy was halted for 4 weeks, to allow increased reproduction of HIV-1. The idea was that the virus would kill lymphocytes that lack the ribozyme, and that ribozyme-expressing immune cells would expand in number.

The treatment regimen was well-tolerated by all patients, and no adverse side effects were observed. The levels of HIV-1 in the blood of patients who received the ribozmye-expressing cells were consistently lower than patients in the control group. Lymphocytes of the CD4+ class – the kind infected by HIV-1 – were also more numerous in the blood of ribozyme-treated patients. These observations demonstrate that a single-dose gene therapy approach has great potential for treating AIDS.

Curiously, no viral mutants emerged in the patients that were resistant to the ribozyme. Nor had such mutations been previously observed in cell culture studies. Why such resistance mutations have not been described is a mystery – a single base change in the region of HIV-1 targeted by the ribozyme should be sufficient to prevent cleavage and inactivation of the viral genome. Because this region of the HIV-1 genome is highly conserved, mutations might produce less fit viruses which cannot compete with ribozyme-sensitive viruses.

Ronald T Mitsuyasu, Thomas C Merigan, Andrew Carr, Jerome A Zack, Mark A Winters, Cassy Workman, Mark Bloch, Jacob Lalezari, Stephen Becker, Lorna Thornton, Bisher Akil, Homayoon Khanlou, Robert Finlayson, Robert McFarlane, Don E Smith, Roger Garsia, David Ma, Matthew Law, John M Murray, Christof von Kalle, Julie A Ely, Sharon M Patino, Alison E Knop, Philip Wong, Alison V Todd, Margaret Haughton, Caroline Fuery, Janet L Macpherson, Geoff P Symonds, Louise A Evans, Susan M Pond, David A Cooper (2009). Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells Nature Medicine DOI: 10.1038/nm.1932

Filed Under: Information Tagged With: gene therapy, HAART, HIV-1, ribozyme

Primary Sidebar

by Vincent Racaniello

Earth’s virology Professor
Questions? virology@virology.ws

With David Tuller and
Gertrud U. Rey

Follow

Facebook, Twitter, YouTube, Instagram
Get updates by RSS or Email

Contents

Table of Contents
ME/CFS
Inside a BSL-4
The Wall of Polio
Microbe Art
Interviews With Virologists

Earth’s Virology Course

Virology Live
Columbia U
Virologia en Español
Virology 101
Influenza 101

Podcasts

This Week in Virology
This Week in Microbiology
This Week in Parasitism
This Week in Evolution
Immune
This Week in Neuroscience
All at MicrobeTV

Useful Resources

Lecturio Online Courses
HealthMap
Polio eradication
Promed-Mail
Small Things Considered
ViralZone
Virus Particle Explorer
The Living River
Parasites Without Borders

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.